SPRY4 and melanoma: Moreover, SPRY4‐IT1 expression has been remarkably correlated with clinical characteristics such as risk, relapse, progression in esophageal squamous cell carcinoma (ESCC) 7, nonsmall‐cell lung cancer (NSCLC) 8, clear cell renal cell carcinoma (ccRCC) 10, gastric cancer 13, 14, bladder cancer 15, and melanoma 16.